State-Of-The-Art Manufacturing Facility Opens in Andover

Our newly opened, state-of-the-art clinical manufacturing facility in Andover, Mass. will expand the capacity of colleagues dedicated to the development and production of high-quality complex biologics and vaccines. With its modular and flexible design allowing clinical and commercial products to be manufactured simultaneously, the 175,000 square foot facility will fully enable our BioTherapeutics Pharmaceutical Sciences organization.

One Andover colleague, Timothy Hickling, an Associate Research Fellow, is part of an Andover team helping to design more advanced biotherapeutic medicines that can evade detection by the immune system. "We're working to design drugs that are stealthy, that can get in and do their work without an immune response," says Timothy.

Biologic medicines have improved the lives of many patients with chronic autoimmune conditions like rheumatoid arthritis, Crohn’s disease, multiple sclerosis, and even some cancers. But, over time, some patients can develop immunity to these medicines, which are made from living cells.

Find out how Timothy and his team are using computer modelling and DNA sequencing to develop biologic medicines on Get Science.

To learn more about the Andover Clinical Manufacturing Facility (ACMF), read the release.